- Home
- FAMI vs EYEN Comparison
FAMI vs EYEN Comparison
Compare FAMI & EYEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FAMI
- EYEN
- Stock Information
- Founded
- FAMI 2015
- EYEN 2014
- Country
- FAMI China
- EYEN United States
- Employees
- FAMI N/A
- EYEN N/A
- Industry
- FAMI Packaged Foods
- EYEN Biotechnology: Pharmaceutical Preparations
- Sector
- FAMI Consumer Staples
- EYEN Health Care
- Exchange
- FAMI Nasdaq
- EYEN Nasdaq
- Market Cap
- FAMI 3.1M
- EYEN 3.7M
- IPO Year
- FAMI 2018
- EYEN 2018
- Fundamental
- Price
- FAMI $0.16
- EYEN $1.62
- Analyst Decision
- FAMI
- EYEN Hold
- Analyst Count
- FAMI 0
- EYEN 4
- Target Price
- FAMI N/A
- EYEN $2.00
- AVG Volume (30 Days)
- FAMI 4.4M
- EYEN 142.6K
- Earning Date
- FAMI 03-21-2025
- EYEN 03-25-2025
- Dividend Yield
- FAMI N/A
- EYEN N/A
- EPS Growth
- FAMI N/A
- EYEN N/A
- EPS
- FAMI N/A
- EYEN N/A
- Revenue
- FAMI $64,131,332.00
- EYEN $31,832.00
- Revenue This Year
- FAMI N/A
- EYEN $23,413.60
- Revenue Next Year
- FAMI N/A
- EYEN $400.98
- P/E Ratio
- FAMI N/A
- EYEN N/A
- Revenue Growth
- FAMI N/A
- EYEN 2557.10
- 52 Week Low
- FAMI $0.15
- EYEN $1.43
- 52 Week High
- FAMI $0.94
- EYEN $142.40
- Technical
- Relative Strength Index (RSI)
- FAMI 24.69
- EYEN 32.65
- Support Level
- FAMI $0.23
- EYEN $1.52
- Resistance Level
- FAMI $0.29
- EYEN $1.66
- Average True Range (ATR)
- FAMI 0.02
- EYEN 0.16
- MACD
- FAMI -0.01
- EYEN 0.19
- Stochastic Oscillator
- FAMI 9.79
- EYEN 34.55
About FAMI Farmmi Inc.
Farmmi Inc is a supplier of agricultural products. The products of the company are Shiitake Mushroom, Mu Er Mushroom and other edible fungi and other agricultural products. The majority of products are sold in mainland China.
About EYEN Eyenovia Inc.
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.